Company news

Ensysce Biosciences, Inc. news in 2021

Ensysce Biosciences, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection

December 14, 2021

Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids

November 29, 2021

Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

November 14, 2021

Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing

November 7, 2021

Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

October 25, 2021

Ensysce Biosciences Announces $15 Million Convertible Note Financing

September 26, 2021

Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614

September 7, 2021

Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates

August 15, 2021

Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof”

August 4, 2021

Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development

July 25, 2021

Ensysce Biosciences to Host Virtual Investor Day on July 27, 2021

July 20, 2021

Ensysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection

July 7, 2021

Decks in 2021